Abstract
Major Depressive Disorder (MDD) is a highly prevalent, severe mental health condition that constitutes one of the leading causes of disability worldwide. While recent animal studies suggest a causal role of the gut microbiome in the pathophysiology of MDD models, evidence in humans is still unclear due to small sample sizes, inconsistent clinical assessment of MDD diagnosis, and methodological limitations regarding causal inference in cross-sectional data. Here, we explicitly address these shortcomings to investigate the potential causal link between the gut microbiome and MDD: First, we replicate previous findings using one of the largest multicenter MDD cohorts for which microbiome data and in-depth diagnostic assessment are available (N=1,269 MDD patients and controls). We find a significant difference between healthy controls and MDD patients for the relative abundance of the four taxa Eggerthella, Hungatella, Coprobacillus, and Lachnospiraceae FCS020. Second, we employ state-of-the-art, fully data-driven causal inference tools within Judea Pearl’s framework, allowing us to derive model constraints from the data rather than relying on potentially strong, unrealistic assumptions. Using this approach, we found data-driven evidence for Eggerthella and Hungatella as causal contributors to MDD. Furthermore, we show that Eggerthella and Hungatella abundances are associated with MDD beyond the influence of body mass index, identifying two distinct pathways linking MDD to the gut microbiome. Finally, the difference in relative abundance of these taxa between healthy and MDD patients was independent of antidepressant medication. Our study provides the first evidence for a potential causal role of gut-microbiota in the pathophysiology of depression in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by the consortia grants from the German Research Foundation (DFG) SFB/TRR 393 (project grant no 521379614), the European Unions Horizon 2020 Research and Innovation Program under grant agreement No. 847879 and the Hessian Ministry of Science and Arts (HMWK) LOEWE program (LOEWE Centre DYNAMIC). This work is part of the German multicenter consortium Neurobiology of Affective Disorders. A translational perspective on brain structure and function, funded by the German Research Foundation (Deutsche Forschungsgemeinschaft DFG; Forschungsgruppe/Research Unit FOR2107). Principal investigators (PIs) with respective areas of responsibility in the FOR2107 consortium are: Work Package WP1, FOR2107/MACS cohort and brainimaging: Tilo Kircher (speaker FOR2107; DFG grant numbers KI588/14-1, KI588/14-2, KI588/20-1, KI588/22-1), Udo Dannlowski (co-speaker FOR2107; DA 1151/5-1, DA 1151/5-2, DA1151/6-1), Axel Krug (KR 3822/5-1, KR 3822/7-2), Igor Nenadic (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO 4291/3-1). WP2, animal phenotyping: Markus Woehr (WO 1732/4-1, WO 1732/4-2), Rainer Schwarting (SCHW 559/14-1, SCHW 559/14-2). WP3, miRNA: Gerhard Schratt (SCHR 1136/3-1, 1136/3-2). WP4, immunology, mitochondriae: Judith Alferink (AL 1145/5-2), Carsten Culmsee (CU 43/9-1, CU 43/9-2), Holger Garn (GA 545/5-1, GA 545/7-2). WP5, genetics: Marcella Rietschel (RI 908/11-1, RI 908/11-2), Markus Noethen (NO 246/10-1, NO 246/10-2), Stephanie Witt (WI 3439/3-1, WI 3439/3-2). WP6, multi‑method data analytics: Andreas Jansen (JA 1890/7-1, JA 1890/7-2), Tim Hahn (HA 7070/2-2), Bertram Mueller-Myhsok (MU1315/8-2), Astrid Dempfle (DE 1614/3-1, DE 1614/3-2). CP1, biobank: Petra Pfefferle (PF 784/1-1, PF 784/1-2), Harald Renz (RE 737/20-1, 737/20-2). CP2, administration. Tilo Kircher (KI 588/15-1, KI 588/17-1), Udo Dannlowski (DA 1151/6-1), Carsten Konrad (KO 4291/4-1). Data access and responsibility: All PIs take responsibility for the integrity of the respective study data and their components. All authors and coauthors had full access to all study data. Acknowledgements and members by Work Package (WP): WP1: Henrike Broehl, Katharina Brosch, Bruno Dietsche, Rozbeh Elahi, Jennifer Engelen, Ulrika Evermann, Sabine Fischer, Jessica Heinen, Svenja Klingel, Felicitas Meier, Tina Meller, Julia-Katharina Pfarr, Kai Ringwald, Torsten Sauder, Simon Schmitt, Frederike Stein, Lea Teutenberg, Florian Thomas-Odenthal, Annette Tittmar, Adrian Wroblewski, Paula Usemann, Dilara Yueksel (Dept. of Psychiatry, Marburg University). Mechthild Wallnig, Rita Werner (Core-Facility Brainimaging, Marburg University). Carmen Schade-Brittinger, Maik Hahmann (Coordinating Centre for Clinical Trials, Marburg). Michael Putzke (Psychiatric Hospital, Friedberg). Rolf Speier, Lutz Lenhard (Psychiatric Hospital, Haina). Birgit Koehnlein (Psychiatric Practice, Marburg). Peter Wulf, Juergen Kleebach, Achim Becker (Psychiatric Hospital Hephata, Schwalmstadt-Treysa). Ruth Baer (Care facility Bischoff, Neukirchen). Matthias Mueller, Michael Franz, Siegfried Scharmann, Anja Haag, Kristina Spenner, Ulrich Ohlenschlaeger (Psychiatric Hospital Vitos, Marburg). Matthias Mueller, Michael Franz, Bernd Kundermann (Psychiatric Hospital Vitos, Giessen). Christian Buerger, Katharina Dohm, Fanni Dzvonyar, Verena Enneking, Stella Fingas, Kira Flinkenfluegel, Katharina Foerster, Janik Goltermann, Dominik Grotegerd, Hannah Lemke, Susanne Meinert, Nils Opel, Ronny Redlich, Jonathan Repple, Katharina Thiel, Kordula Vorspohl, Bettina Walden, Lena Waltemate, Alexandra Winter, Dario Zaremba (Dept. of Psychiatry, University of Muenster). Harald Kugel, Jochen Bauer, Walter Heindel, Birgit Vahrenkamp (Dept. of Clinical Radiology, University of Muenster). Gereon Heuft, Gudrun Schneider (Dept. of Psychosomatics and Psychotherapy, University of Muenster). Thomas Reker (LWL-Hospital Muenster). Gisela Bartling (IPP Muenster). Ulrike Buhlmann (Dept. of Clinical Psychology, University of Muenster), Robert Nitsch (Institute for Translational Neuroscience, University of Muenster). WP2: Marco Bartz, Miriam Becker, Christine Bloecher, Annuska Berz, Moria Braun, Ingmar Conell, Debora dalla Vecchia, Darius Dietrich, Ezgi Esen, Sophia Estel, Jens Hensen, Ruhkshona Kayumova, Theresa Kisko, Rebekka Obermeier, Anika Puetzer, Nivethini Sangarapillai, oezge Sungur, Clara Raithel, Tobias Redecker, Vanessa Sandermann, Finnja Schramm, Linda Tempel, Natalie Vermehren, Jakob Voerckel, Stephan Weingarten, Maria Willadsen, Cueneyt Yildiz (Faculty of Psychology, Marburg University). WP4: Jana Freff (Dept. of Psychiatry, University of Muenster). Susanne Michels, Goutham Ganjam, Katharina Elsaesser (Faculty of Pharmacy, Marburg University). Felix Ruben Picard, Nicole Loewer, Thomas Ruppersberg (Institute of Laboratory Medicine and Pathobiochemistry, Marburg University). WP5: Helene Dukal, Christine Hohmeyer, Lennard Stuetz, Viola Lahr, Fabian Streit, Josef Frank, Lea Sirignano (Dept. of Genetic Epidemiology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University). Stefanie Heilmann-Heimbach, Stefan Herms, Per Hoffmann (Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn). Andreas J. Forstner (Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn; Centre for Human Genetics, Marburg University). WP6: Anastasia Benedyk, Miriam Bopp, Roman Kessler, Maximilian Lueckel, Verena Schuster, Christoph Vogelbacher (Dept. of Psychiatry, Marburg University). Jens Sommer, Olaf Steinstraeter (Core-Facility Brainimaging, Marburg University). Thomas W.D. Moebius (Institute of Medical Informatics and Statistics, Kiel University). CP1: Julian Glandorf, Fabian Kormann, Arif Alkan, Fatana Wedi, Lea Henning, Alena Renker, Karina Schneider, Elisabeth Folwarczny, Dana Stenzel, Kai Wenk, Felix Picard, Alexandra Fischer, Sandra Blumenau, Beate Kleb, Doris Finholdt, Elisabeth Kinder, Tamara Wuest, Elvira Przypadlo, Corinna Brehm (Comprehensive Biomaterial Bank Marburg, Marburg University). The FOR2107 cohort project (WP1) was approved by the Ethics Committees of the Medical Faculties, University of Marburg (AZ: 07/14) and University of Muenster (AZ: 2014-422-b-S). SET was funded by the Leistungszentrum Innovative Therapeutics (TheraNova) funded by the Fraunhofer Society and the Hessian Ministry of Science and Art, the Bundesministerium fuer Bildung und Forschung (BMBF, Federal Ministry of Education) - 01EO2102 INITIALISE Advanced Clinician Scientist Program and the REIss foundation. RN was funded by the German Research Foundation (DFG/CRC 1451/A07). Biomedical financial interests or potential conflicts of interest: Tilo Kircher received unrestricted educational grants from Servier, Janssen, Recordati, Aristo, Otsuka, neuraxpharm. Markus Woehr is scientific advisor of Avisoft Bioacoustics. Sarah Kittel-Schneider received speakers honoraria from Janssen. Andreas Reif has received honoraria for lectures and/or advisory boards from Janssen, Boehringer Ingelheim, COMPAss, SAGE/Biogen, LivaNova, Medice, Shire/Takeda, MSD and cyclerion. Also, he has received research grants from Medice and Janssen. Microbiota sequencing @IKMB received infrastructure support from the DFG Research Unit 5042 miTarget and the DFG Excellence Cluster 2167 Precision Medicine in Chronic Inflammation (PMI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The FOR2107 cohort project (WP1) was approved by the Ethics Committees of the Medical Faculties, University of Marburg (AZ: 07/14) and University of Muenster (AZ: 2014-422-b-S).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.